Dialysis provider DaVita Inc. (NYSE:DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.
Dialysis provider DaVita Inc. (NYSE:DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
October 10, 2025 – The financial markets are currently experiencing a pronounced divergence, with a select group of companies reaching new 52-week highs, propelled by technological innovation and strategic market positioning, while established consumer and industrial players slide to 52-week lows, grappling with shifting economic landscapes and sector-specific headwinds. This bifurcated
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how outpatient & specialty care stocks fared in Q2, starting with DaVita (NYSE:DVA).
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Shares of dialysis provider DaVita Inc. (NYSE:DVA)
fell 3.1% in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
DaVita reported a ransomware attack affecting 2.7 million patients, posted Q2 earnings above estimates, and authorized a $2 billion boost to its share buyback plan.
The dialysis provider said care at its nearly 3,000 clinics and at-home programs continued without interruption, though the attack caused temporary disruptions and $13.5 million in added costs.
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
